In Greek and Roman mythology, Apollo is the god of truth, prophecy and healing. A more than fitting name for a new Hamburg-based venture capital (VC) firm, which plans to focus exclusively on diseases that manifest as humans age.
Apollo Ventures plans to provide investments for research looking at arthritis, dementia, age-related macular degeneration, hearing loss, osteoporosis, Alzheimer’s disease and possibly diabetes.
“Apollo helps scientists and entrepreneurs build biotech companies with innovative strategic pathways to bring the first real medicines treating the damage of aging to patients,” the VC, co-founded by TruVenturo founder Nils Regge, write on their website.
Partners of the young VC include Regge, James Payer, who previously worked for as a consultant for McKinsey and Company’s biotech practice and Ole Mensching, who was also involved with TruVenturo and founded CareerTeam, a headhunting agency. When approached by the Heureka, the VC said they were not ready to make an official statement. They launched in June 2016.
“Apollo serves as a strategic partner to scientists, helping them take their first steps as a biotechnology company.”
The VC, which has an international focus, has not released how much money they have to invest in early stage companies and joins a handful of other VCs, like Project A, Earlybird and Digital Health VC, as another player in the healthcare arena.